Clinical Trials Logo
  1. Home
  2. Drug Intolerance
  3. NCT03052218

Evaluation of Pupillometry for cyp2d6 Phenotyping in Children Treated With Tramadol — PUPICYP  

Drug Effect Clinical Trial

Official title:
Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated With Tramadol

Clinical Trial Summary

Pupillometry will be performed before administration of tramadol, at T0 and then 1 to twice per hour in children having received tramadol as a pain killer as part of his/her routine care. Pupillometry measurement will be correlate to CYP2D6 phenotype and CYP2D6 genetic score

Clinical Trial Description

The proposed study is a single-center, observational and prospective study which will be conducted at the Pediatric Emergency Department, Geneva Children's Hospital. This study will begin in January 2016 and will last one year. 53 patients are planned to be enrolled. Children receiving oral tramadol as a pain killer at the emergency department, as part of their routine care, will be informed of the current study. Patients willing to participate will be included in the study after signing the inform consent (or respectively his/her parents or legal guardians). A unique oral dose of dextromethorphan (0.15 mg/kg) will be given to the participant for CYP2D6 phenotyping (T0). Two hours later, capillary whole blood will be sampled to 1) measure the metabolic ratio dextrorphan/dextromethorphan (MRDOR/DEM) in order to determine CYP2D6 phenotype (validated metrics for CYP2D6 phenotyping), 2) measure tramadol and its active metabolite O-desmethyltramadol (M1), and 3) to genotype for CYP2D6. Saliva sample will also be performed to genotype for CYP2D6. Pupillometry will be performed before administration of tramadol, at T0 and then 1 to twice per hour, throughout the patient's stay at the emergency department. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03052218
Study type Interventional
Source University Hospital, Geneva
Contact
Status Terminated
Phase N/A
Start date March 1, 2017
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Completed NCT04166890 - Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia Phase 4
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04037774 - Comparision of Different Doses of Dexmedetomidine With Low Dose Bupivacaine in Selective Spinal Anesthesia. Phase 4
Recruiting NCT05113420 - The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
Completed NCT03801629 - Neuroimmune Effects of Opioid Administration Phase 1
Completed NCT04052776 - Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES Phase 1
Completed NCT04037085 - Ketamine to Improve Recovery After Cesarean Delivery - Part 1 Phase 2
Completed NCT05050071 - Evaluation of Antibacterial Effect of Allium Sativum, Calcium Hydroxide and Their Combination in Infected Mature Teeth Phase 2/Phase 3
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Completed NCT06238154 - Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds Phase 4
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Recruiting NCT05300152 - Pulpotomy Medications in Primary Teeth N/A
Recruiting NCT04594889 - Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia N/A
Not yet recruiting NCT05018936 - Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Phase 2/Phase 3
Completed NCT04245774 - Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia Phase 4
Completed NCT04449536 - Cysteine-lowering Treatment With Mesna Phase 1
Recruiting NCT05975255 - Dose Finding Study for Remimazolam in Children Phase 2
Active, not recruiting NCT04254731 - Effects of Switching From Racemic Methadone to R-methadone on QTc Intervals Phase 4
Completed NCT03635684 - Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen Phase 2